Literature DB >> 16981254

Screening in liver disease.

Paolo Del Poggio, Marzio Mazzoleni.   

Abstract

A disease is suitable for screening if it is common, if the target population can be identified and reached and if both a good screening test and an effective therapy are available. Of the most common liver diseases only viral hepatitis and genetic hemochromatosis partially satisfy these conditions. Hepatitis C is common, the screening test is good and the therapy eliminates the virus in half of the cases, but problems arise in the definition of the target population. In fact generalized population screening is not endorsed by international guidelines, although some recommend screening immigrants from high prevalence countries. Opportunistic screening (case finding) of individuals with classic risk factors, such as transfusion before 1992 and drug addiction, is the most frequently used strategy, but there is disagreement whether prison inmates, individuals with a history of promiscuous or traumatic sex and health care workers should be screened. In a real practice setting the performance of opportunistic screening by general practitioners is low but can be ameliorated by training programs. Screening targeted to segments of the population or mass campaigns are expensive and therefore interventions should be aimed to improve opportunistic screening and the detection skills of general practitioners. Regarding genetic hemochromatosis there is insufficient evidence for population screening, but individual physicians can decide to screen racial groups with a high prevalence of the disease, such as people in early middle age and of northern European origin. In the other cases opportunistic screening of high risk individuals should be performed, with a high level of suspicion in case of unexplained liver disease, diabetes, juvenile artropathy, sexual dysfunction and skin pigmentation.

Entities:  

Mesh:

Year:  2006        PMID: 16981254      PMCID: PMC4088191          DOI: 10.3748/wjg.v12.i33.5272

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  92 in total

Review 1.  Uses and abuses of screening tests.

Authors:  David A Grimes; Kenneth F Schulz
Journal:  Lancet       Date:  2002-03-09       Impact factor: 79.321

Review 2.  [Treatment of hepatitis C. Paris 27-28 February 2002].

Authors: 
Journal:  Ann Med Interne (Paris)       Date:  2002-11

3.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

Review 4.  Hepatitis B virus infection.

Authors:  W M Lee
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

5.  Atrial fibrillation in elderly patients: prevalence and comorbidity in general practice.

Authors:  M Langenberg; B S Hellemons; J W van Ree; F Vermeer; J Lodder; H J Schouten; J A Knottnerus
Journal:  BMJ       Date:  1996-12-14

6.  Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients.

Authors:  N Milman; P Pedersen; T á Steig; K E Byg; N Graudal; K Fenger
Journal:  Ann Hematol       Date:  2001-10-11       Impact factor: 3.673

7.  Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA.

Authors:  Ernest Beutler; Vincent J Felitti; James A Koziol; Ngoc J Ho; Terri Gelbart
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

8.  Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis.

Authors:  M J Alter; P J Coleman; W J Alexander; E Kramer; J K Miller; E Mandel; S C Hadler; H S Margolis
Journal:  JAMA       Date:  1989-09-01       Impact factor: 56.272

9.  Report from Working Group 3 (the Czech Republic, Denmark, Finland, Norway, The Netherlands, Slovakia, Sweden and the UK).

Authors:  S Iwarson
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

10.  Epidemiology and Prevention of Hepatitis B Virus Infection.

Authors:  Jinlin Hou; Zhihua Liu; Fan Gu
Journal:  Int J Med Sci       Date:  2005-01-05       Impact factor: 3.738

View more
  1 in total

1.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.